Effect of ileal bile acid transporter inhibitor against Achromobacter in oral microbiota 2391

Abstract Description Aspiration pneumonia (AP) in immunocompromised hosts is a very serious health problem with a high mortality rate. Achromobacter is known as a causative pathogen which migrate from oral microbiota to lung by aspiration and those hosts cannot eliminate this pathogen. Reducing the number of pathogens in oral microbiota is a strategy to control AP caused by Achromobacter. Therefore, a simple and long-lasting method for reducing the pathogens in oral microbiota is needed. An ileal bile acid transporter inhibitor (IBATi) is used for patients with constipation. We investigated the effect of IBATi administration on reducing Achromobacter in oral microbiota of mice by 16S rRNA sequence analysis. In the results, Achromobacter xylosoxidans of oral microbiota was detected (2.3 ± 1.2 % of total OTUs) in mice with normal diet (normal mice) and large number of this pathogen was found in HFD diet fed mice (Achromobacter mice) (10.3 ± 3.4 %). When 10 mg/g of IBATi was administered through the stomach once a day in Achromobacter mice for 4 weeks, the pathogen decreased to the same level as in normal mice. In α-diversity of oral microbiota, Chao1 index in Achromobacter mice (70.8 ± 4.9) was significantly lower than that in normal mice (82.4± 9.5). When Achromobacter mice was treated with IBATi, Chao1 index was recovered to the same level as in normal mice. By reducing the pathogen in oral microbiota with IBATi, it may be possible to change in oral microbiota and prevent the incidence of AP. Funding Sources Supported by JSPS KAKENHI, JP 24K11096, 22K0844, 20K08831 Topic Categories Microbial, Parasitic, and Fungal Immunology (MPF)